Breast cancer is one of the most common malignancies among women, representing
nearly 30% of newly diagnosed cancers every year. Till date, various therapeutic interventions,
including surgery, chemotherapy, hormonal therapy, and radiotherapy are available and are known to
cause a significant decline in the overall mortality rate. However, therapeutic resistance, recurrence
and lack of treatment in metastasis are the major challenges that need to be addressed. Increasing
evidence suggests the presence of cancer stem cells (CSCs) in heterogeneous population of breast tumors capable of selfrenewal
and differentiation and is considered to be responsible for drug resistance and recurrence. Therefore, compound
that can target both differentiated cancer cells, as well as CSCs, may provide a better treatment strategy. Due to safe
nature of dietary agents and health products, investigators are introducing them into clinical trials in place of
chemotherapeutic agents.This current review focuses on phytochemicals, mainly flavonoids that are in use for breast
cancer therapy in preclinical phase. As phytochemicals have several advantages in breast cancer and cancer stem cells,
new synthetic series for breast cancer therapy from analogues of most potent natural molecule can be developed via
rational drug design approach.
Keywords: Bioavailability, breast cancer, cancer stem cells, cannabinoids, flavonoids, phytochemicals, tyrosine kinase.
Rights & PermissionsPrintExport